Commentary: Using QbTest for monitoring pharmacological treatment response in ADHD - are we there yet?

Bellato A 1 , Parlatini V 1 , Groom MJ 2 , Hall CL 2 , Hollis C 2 , Simonoff E 3 Show all authors , Thapar A 4 , Cortese S 5

Affiliations 

  • 1 School of Psychology, University of Southampton, Southampton, UK
  • 2 NIHR MindTech HealthTech Research Centre, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, UK
  • 3 Department of Child and Adolescent Psychiatry, King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK
  • 4 Division of Psychological Medicine and Clinical Neurosciences, Wolfson Centre for Young People's Mental Health, Cardiff University School of Medicine, Cardiff, UK
  • 5 Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK
J Child Psychol Psychiatry, 2024 Nov 08.
PMID: 39513414 DOI: 10.1111/jcpp.14071

Abstract

Individuals with attention-deficit/hyperactivity disorder (ADHD) exhibit varied responses to pharmacological treatments (e.g. stimulants and non-stimulants). Accurately and promptly detecting treatment-related improvements, response failure, or deterioration poses significant challenges, as current monitoring primarily relies on subjective ratings. In this commentary, we critically evaluate the evidence supporting the use of QbTest for objectively monitoring ADHD treatment response in clinical practice. We also offer recommendations for future research, advocating for rigorous clinical trials and longitudinal studies to further explore the potential utilisation of QbTest and other tools for monitoring treatment responses in individuals with ADHD.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications